These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37834964)

  • 21. Effects of platelet and phospholipids on clot formation activated by a small amount of tissue factor.
    Wada H; Shiraki K; Matsumoto T; Ohishi K; Shimpo H; Shimaoka M
    Thromb Res; 2020 Sep; 193():146-153. PubMed ID: 32559572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The combination of emicizumab and recombinant factor VIII in plasma: Which assays can we use for accurate measurement?
    Bowyer AE; Maclean RM; Kitchen S
    Int J Lab Hematol; 2023 Jun; 45(3):368-376. PubMed ID: 36710421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measurement of recombinant porcine factor VIII in patients with congenital haemophilia A and inhibitors in the presence of emicizumab.
    Pfrepper C; Klamroth R; Ettingshausen CE; Petros S; Siegemund A; Siegemund T
    Haemophilia; 2024 Mar; 30(2):545-553. PubMed ID: 38343119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays.
    Adamkewicz JI; Chen DC; Paz-Priel I
    Thromb Haemost; 2019 Jul; 119(7):1084-1093. PubMed ID: 31064025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Evaluation of Hemostatic Abnormalities Using a CWA-Small Amount Tissue Factor Induced FIX Activation Assay in Major Orthopedic Surgery Patients.
    Hasegawa M; Tone S; Wada H; Naito Y; Matsumoto T; Yamashita Y; Shimaoka M; Sudo A
    Clin Appl Thromb Hemost; 2021; 27():10760296211012094. PubMed ID: 34027710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Study protocol for assessment of the coagulation potential of concomitantly used factor VIII concentrates in patients with haemophilia A with emicizumab prophylaxis (CAGUYAMA Study): a multicentre open-label non-randomised clinical trial.
    Takeyama M; Ozu N; Kasama S; Kasahara M; Matsumoto M; Shima M; Nogami K
    BMJ Open; 2023 Jul; 13(7):e072565. PubMed ID: 37429679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in the Composition of Activated Partial Thromboplastin Time (APTT) Reagents Affect Clot Waveform Analysis.
    Kato K; Hatayama Y; Shimohiro H; Ichikawa H; Fukuda T
    Yonago Acta Med; 2022 Aug; 65(3):226-230. PubMed ID: 36061578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII.
    Shimonishi N; Nogami K; Ogiwara K; Matsumoto T; Nakazawa F; Soeda T; Hirata M; Arai N; Shima M
    Haemophilia; 2020 May; 26(3):e97-e105. PubMed ID: 32157756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factor VIII: A Dynamic Modulator of Hemostasis and Thrombosis in Trauma.
    Tanaka KA; Terada R; Butt AL; Mazzeffi MA; McNeil JS
    Anesth Analg; 2023 May; 136(5):894-904. PubMed ID: 37058725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generation.
    Bowyer AE; Kitchen S; Ezban M
    J Thromb Haemost; 2023 Mar; 21(3):480-487. PubMed ID: 36696203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clot waveform analysis using CS-2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A.
    Matsumoto T; Nogami K; Tabuchi Y; Yada K; Ogiwara K; Kurono H; Arai N; Shima M
    Haemophilia; 2017 Sep; 23(5):e427-e435. PubMed ID: 28750470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
    Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
    Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of emicizumab-neutralizing antibodies on activated partial thromboplastin time-based clotting time test results in patients treated with emicizumab.
    Novembrino C; Boscolo-Anzoletti M; Galbiati E; Shinohara S; Peyvandi F
    Res Pract Thromb Haemost; 2023 Nov; 7(8):102260. PubMed ID: 38193066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Hemodilution on Clot Waveform Analysis Parameters, Clotting Factors, and Thrombin Generation Assays in a Dilutional Model Based on Analysis of 11 Healthy Male Blood Donors.
    Ichikawa J; Okazaki R; Fukuda T; Yoon D; Komori M
    Med Sci Monit; 2022 Oct; 28():e937368. PubMed ID: 36225091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Laboratory issues in gene therapy and emicizumab.
    Bowyer AE; Lowe AE; Tiefenbacher S
    Haemophilia; 2021 Feb; 27 Suppl 3():142-147. PubMed ID: 32469128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overall hemostasis potential and aPTT-clot waveform analysis as powerful laboratory diagnostic tools for identification of hemophilia A patients with unexpected bleeding phenotype.
    Milos M; Coen Herak D; Mahmoud Hourani Soutari N; Pavic J; Zupancic-Salek S; Zadro R; Antovic JP
    Int J Lab Hematol; 2021 Apr; 43(2):273-280. PubMed ID: 32964648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regression Analysis to Estimate the Factor VIII Activity of Patients with Hemophilia A Without Inhibitor who Received Emicizumab Therapy.
    Hatayama Y; Motokura T; Hosoda Y; Suzuki S; Namba H; Kato K; Kojima N; Horie T; Iwamoto T; Yamashita N; Ichikawa H; Fukuda T
    Clin Appl Thromb Hemost; 2022; 28():10760296221082992. PubMed ID: 35225012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of the phenotypic severity of hemophilia A: using rotational thromboelastometry (ROTEM) and APTT-clot waveform analysis.
    Gupta D; Arya V; Dass J; Gupta N; Kalra M; Sachdeva A; Kotwal J
    Blood Res; 2024 May; 59(1):19. PubMed ID: 38743166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterogeneous coagulant potential of emicizumab in neonatal factor VIII-deficient plasma.
    Takeyama M; Furukawa S; Onishi T; Noguchi-Sasaki M; Shima M; Nogami K
    Pediatr Blood Cancer; 2022 Jul; 69(7):e29731. PubMed ID: 35441786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophiliac patients.
    Amiral J; Seghatchian J
    Transfus Apher Sci; 2018 Jun; 57(3):363-369. PubMed ID: 29895509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.